Sergio Bracarda
Ospedale Sacro Cuore Don Calabria · 583 works · 27,811 citations · h-index 62
Top works
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
- Phase 3 trial of everolimus for metastatic renal cell carcinoma
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
- Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
- Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
- Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival
- Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research.
- IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC)
- Short- and long-term safety with sunitinib in an expanded access trial in metastatic renal cell carcinoma (mRCC)
- Predictive Factors of Delayed Emesis in Cisplatin-Treated Patients and Antiemetic Activity and Tolerability of Metoclopramide or Dexamethasone
- Intra and interobserver variability in cancer patients' performance status assessed according to Karnofsky and ECOG scales
- Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
- Contemporary Role of Androgen Deprivation Therapy for Prostate Cancer
- Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel
- Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
- Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma